Rathburn Featured on WisBusiness Podcast on California Consumer Privacy Act
27 February 2020
Partner Jennifer Rathburn was featured on the WisBusiness podcast, discussing the California law and how it could impact Wisconsin based businesses operating in California.
“How we see most companies come under that law is if they have over $25 million of annual gross revenues,” Rathburn said. “Other ways which are not as typical, is if you derive 50 percent or more of your assets from essentially selling data… or if you are buying or selling more than 50,000 California residents’ consumer data.”
Rathburn goes on to explain steps that Wisconsin businesses can take to ensure they are in compliance with the CCPA. You can listen to the full episode, or download it here.
“How we see most companies come under that law is if they have over $25 million of annual gross revenues,” Rathburn said. “Other ways which are not as typical, is if you derive 50 percent or more of your assets from essentially selling data… or if you are buying or selling more than 50,000 California residents’ consumer data.”
Rathburn goes on to explain steps that Wisconsin businesses can take to ensure they are in compliance with the CCPA. You can listen to the full episode, or download it here.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”